Hallura

Company Overview

Snapshot

Founded in August 2017 by Stephane Meunier, Hallura operates with 11–50 employees. The company has secured $7 million in total capital across two funding rounds, attracting investors including Alon MedTech Ventures. In November 2019, Hallura closed a $7 million Series A financing round.

Business overview

Hallura is a Health Tech & Life Sciences company developing next-generation hyaluronic acid (HA) dermal fillers for aesthetic medicine. Its core technology, BiOLinkMatrix, utilizes a proprietary cross-linking mechanism to enhance the longevity and natural feel of HA dermal fillers, addressing limitations of existing products. Hallura's products are designed for non-invasive aesthetic treatments, including skin rejuvenation, fine and deep line smoothing, and volume restoration, serving the cosmetics and medical devices industries within the broader healthcare and life sciences markets.

Strategic signal

In November 2022, Hallura announced the development of its BiOLinkMatrix platform, a proprietary technology for HA dermal fillers inspired by the 2022 Nobel Prize for Click Chemistry. This innovation signals Hallura's commitment to advanced scientific principles in product development, positioning it to potentially disrupt the aesthetic medical market with safer, more effective dermal fillers and offering a strong growth signal to investors interested in cutting-edge medical aesthetics.

Company Intelligence Q&A

What is Hallura's core technology?

Hallura's core technology is the BiOLinkMatrix platform, which revolutionizes the cross-linking of Hyaluronic Acid (HA) in dermal fillers. This technology, inspired by the 2022 Nobel Prize for Click Chemistry, aims to provide safer and more natural aesthetic results.

When did Hallura complete its European multi-site clinical trial?

In March 2022, Hallura announced successful topline results from its European multi-site clinical trial for its BiOLinkMatrix HA aesthetic dermal fillers. The trial evaluated the safety and effectiveness of three gels for lip enhancement, nasolabial folds correction, and cheek enhancement.

Who is a key leader on Hallura's Board of Directors?

In July 2020, Hallura appointed Paul Navarre as an independent director to its Board of Directors. Navarre brings over 25 years of experience in the pharmaceuticals and consumer goods industries.

What was Hallura's last disclosed funding round?

In November 2019, Hallura closed a $7 million Series A financing round. This funding was led by a group of private investors, including leading plastic surgeons and dermatologists.

What markets does Hallura target with its products?

Hallura's products are designed for the aesthetic medicine market, focusing on non-invasive treatments for skin rejuvenation, fine and deep line smoothing, and volume restoration in areas like lips and mid-face. The company aims to serve the growing demand for soft, natural aesthetic outcomes.